A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs

This publication has 65 references indexed in Scilit:

• Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10)
  Vaccine, 1999
• Expression of Herpes Simplex Virus DNA Fragments Located in Epidermal Keratinocytes and Germinative Cells Is Associated with the Development of Erythema Multiforme Lesions
  Journal of Investigative Dermatology, 1997
• A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease
  The Journal of Infectious Diseases, 1997
• Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease
  British Journal of Dermatology, 1996
• Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vagin
  Vaccine, 1994
• Quantity of Latency-Associated Transcript Produced by Herpes Simplex Virus Is Not Predictive of the Frequency of Experimental Recurrent Genital Herpes
  The Journal of Infectious Diseases, 1994
• Expression of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for virus growth and neoplastic transformation
  Journal of General Virology, 1992
• Clinical and subclinical HSV infection resulting from exposure to asymptomatic patients
  British Journal of Dermatology, 1990
• Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital Herpes
  The Journal of Infectious Diseases, 1987
• Immunity to Herpes Simplex Virus: Virus Reactivation Modulates Lymphokine Activity
  The Journal of Infectious Diseases, 1985